Half-year report · Q2
2531.TEDINET S100UNIS
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥176.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥339.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥163.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥12.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥23.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥13.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥9.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥16.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥8.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥9.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥447.8bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥437.5bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥420.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥151.4bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥157.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥296.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥280.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥272.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥95.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.1bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥89.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥91.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥29.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥15.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥9.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥46.55 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.09 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.69 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 54.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.2% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥15.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥395m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥89.0bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥88.8bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥227m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.8bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥19.8bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥417m |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.0bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥504m |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥170.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥170.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥732m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥9.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥186.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥176.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥10.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥14.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥6.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥8.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥9.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥9.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥348m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥77.2bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥76.9bn |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥282m |
| jpcrp040300-q2r_E00396-000Takara Bio Groupreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.3bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥19.1bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥19.1bn |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E00396-000Takara Healthcarereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥61.2bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥60.7bn |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥486m |
| jpcrp040300-q2r_E00396-000Takara Shuzo Groupreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥157.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥156.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥768m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥11.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥172.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥163.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥12.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc semi annual consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |